Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-133673
Filing Date
2024-12-05
Accepted
2024-12-05 16:07:19
Documents
47
Period of Report
2024-10-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-20241031.htm   iXBRL 10-Q 1291691
2 EX-31.1 kalv-ex31_1.htm EX-31.1 17741
3 EX-31.2 kalv-ex31_2.htm EX-31.2 15908
4 EX-32.1 kalv-ex32_1.htm EX-32.1 11209
  Complete submission text file 0000950170-24-133673.txt   4823401

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kalv-20241031.xsd EX-101.SCH 639071
49 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20241031_htm.xml XML 738002
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 241529144
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)